Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

mitsubishi tanabe ph-uns adr (MTZXY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
187.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MITSUBISHI TANABE PH-UNS ADR (MTZXY)

Related News

No related news articles were found.

mitsubishi tanabe ph-uns adr (MTZXY) Related Businessweek News

No Related Businessweek News Found

mitsubishi tanabe ph-uns adr (MTZXY) Details

Mitsubishi Tanabe Pharma Corporation manufactures and sells pharmaceuticals in Japan and internationally. The company offers autoimmune drugs, including Remicade agent for rheumatoid arthritis and Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis; and Simponi agent for rheumatoid arthritis. It also provides drugs for diabetes and kidney diseases, such as Kremezin agent for chronic renal failure; and Tanatril agent for hypertension and diabetic nephropathy with type I diabetes mellitus, etc. In addition, the company offers drugs for central nervous system diseases comprising Radicut, a cerebral neuroprotectant; Ceredist agent for spinocerebellar degeneration; Depas, an anti-anxiety agent; and Lexapro, an anti-depressant agent. Further, it provides Maintate agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure, and atrial fibrillation; Talion agent for allergic disorders; Urso agent for the improvement of hepatic, biliary, and digestive function; Anplag, an anti-platelet agent; and Herbesser, an agent for angina pectoris and hypertension. Additionally, the company offers vaccines, such as TETRABIK, a combined vaccine for diphtheria, pertussis, tetanus, and poliomyelitis; and influenza. It also provides over-the-counter products, including herbal and digestive medicines, as well as oral solutions for tonic and nutritional supplement; oral agent for allergic rhinitis; and products for the treatment of skin conditions and recurrent vaginal candidiasis. The company also offers pharmaceutical information and real estate management services; sells generic pharmaceuticals, chemicals, etc.; invests in bio-ventures; and is involved in distribution and warehouse operations. The company was founded in 1678 and is headquartered in Osaka, Japan. Mitsubishi Tanabe Pharma Corporation is a subsidiary of Mitsubishi Chemical Holdings Corporation.

9,065 Employees
Last Reported Date: 06/20/14
Founded in 1678

mitsubishi tanabe ph-uns adr (MTZXY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mitsubishi tanabe ph-uns adr (MTZXY) Key Developments

Neurocrine Biosciences Enters Licensing Agreement with Mitsubishi Tanabe Pharma to Develop and Commercialize VMAT2 Inhibitor NBI-98854

Neurocrine Biosciences Inc. announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation. Mitsubishi Tanabe intends to initially develop NBI-98854 in Japan for the chorea associated with Huntington's disease and tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia. Under the terms of the agreement, Neurocrine will receive an initial payment of $30 million and is eligible to receive up to $85 million in additional milestone payments associated with the development and commercialization of NBI-98854 in Asia. Upon commercialization, Neurocrine will receive royalties on product sales from Mitsubishi Tanabe territories in Asia. Neurocrine will also support Mitsubishi Tanabe's clinical efforts in developing NBI-98854 for patients suffering from the chorea associated with Huntington's disease and tardive dyskinesia.

Mitsubishi Tanabe Pharma Corporation Provides Dividend Guidance for the Year Ending March 31, 2015; Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2014; Provides Earnings Guidance for Full Year for the Fiscal Year Ending March 31, 2015

Mitsubishi Tanabe Pharma Corporation provided projected dividend of ¥20.00 per share for the year ending March 31, 2015, same as a year ago. The company announced consolidated earnings results for the nine months ended December 31, 2014. For the nine months, the company reported net sales of ¥319,777 million against ¥323,210 million a year ago. Operating income was ¥63,588 million against ¥55,526 million a year ago. Ordinary income was ¥64,088 million against ¥57,781 million a year ago. Net income was ¥48,294 million against ¥43,851 million a year ago. Net income per share was ¥86.09 against ¥78.17 a year ago. Income before income taxes and minority interests was ¥69,876 million against ¥67,817 million a year ago. Net cash provided by operating activities was ¥30,907 million against ¥46,094 million a year ago. Purchase of property, plant and equipment was ¥6,468 million compared to ¥9,337 million for the same period a year ago. Purchase of intangible fixed assets was ¥1,096 million compared to ¥1,525 million for the same period a year ago. The company provided earnings guidance for full year for the fiscal year ending March 31, 2015. For the full year, the company expects to report net sales of ¥406,000 million, operating income of ¥60,000 million, ordinary income of ¥61,500 million and net income of ¥40,500 million or ¥72.19 per share.

Mitsubishi Tanabe Pharma Corporation, Q3 2015 Earnings Call, Feb 02, 2015

Mitsubishi Tanabe Pharma Corporation, Q3 2015 Earnings Call, Feb 02, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MTZXY:US $0.00 USD 0.00

MTZXY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MTZXY.
View Industry Companies
 

Industry Analysis

MTZXY

Industry Average

Valuation MTZXY Industry Range
Price/Earnings 23.1x
Price/Sales 2.8x
Price/Book 1.5x
Price/Cash Flow 18.5x
TEV/Sales 2.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MITSUBISHI TANABE PH-UNS ADR, please visit www.mt-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.